SCHEMBL5916638

SCHEMBL5916638

O=c1c2ccccc2[se]n1-c1nccs1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ METAP2 P50579 4/20 0.54
▸ KDM4E B2RXH2 3/20 0.54
▸ ALDH1A1 P00352 3/20 0.54
▸ MAPT P10636 2/20 0.54
▸ G6PD P11413 2/20 0.54
▸ PKM P14618 2/20 0.54
▸ MPI P34949 2/20 0.54
▸ TDP1 Q9NUW8 2/20 0.54
▸ MEN1 O00255 2/20 0.54
▸ HPGD P15428 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ NPSR1 Q6W5P4 2/20 0.54
▸ QSOX1 O00391 1/20 0.54
▸ RGS12 O14924 1/20 0.54
▸ PMM2 O15305 1/20 0.54
▸ PLIN1 O60240 1/20 0.54
▸ GMNN O75496 1/20 0.54
▸ BBOX1 O75936 1/20 0.54
▸ LMNA P02545 1/20 0.54
▸ TP53 P04637 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10501841 0.83 KDM4E (0.41) METAP2KDM4EALDH1A1MAPTG6PD
SCHEMBL5916770 0.80 METAP2 (0.40) METAP2KDM4EALDH1A1MAPTG6PD
SCHEMBL10501508 0.80 METAP2 (0.42) METAP2KDM4EALDH1A1MAPTG6PD
SCHEMBL5916643 0.80 MPI (0.44) METAP2KDM4EALDH1A1MAPTG6PD
SCHEMBL5916810 0.80 METAP2 (0.40) METAP2KDM4EALDH1A1MAPTG6PD
SCHEMBL10742993 0.77 METAP2 (0.53) METAP2KDM4EALDH1A1MAPTG6PD
SCHEMBL5916782 0.77 METAP2 (0.61) METAP2KDM4EALDH1A1MAPTG6PD
SCHEMBL10502494 0.76 TXNRD1 (0.52) METAP2KDM4EALDH1A1MEN1HPGD
SCHEMBL10503662 0.76 EP300 (0.36) KDM4EALDH1A1MAPTG6PDPKM
SCHEMBL5916699 0.76 METAP2 (0.46) METAP2KDM4EALDH1A1MEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060135569-A1 Use of benzisoselenazolone compounds against ischemic myocardial damage INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2006-06-22 — — US claimed
EP-1541145-A1 THE USE OF BENZISOSELENAZOLONE COMPOUNDS AGAINST ISCHEMIC MYOCARDIAL DAMAGE Institute of Materia, Chinese Academy of Medical Sciences (CN) 2005-06-15 — — EP claimed
EP-0100899-B1 BENZISOSELENAZOLONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM A. Nattermann & Cie. GmbH (DE) 1988-06-15 — — EP claimed
EP-0100899-A2 Benzisoselenazolones, process for their preparation and pharmaceutical compositions containing them A. Nattermann & Cie. GmbH (DE) 1984-02-22 — — EP claimed
US-20060135569-A1 Use of benzisoselenazolone compounds against ischemic myocardial damage INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2006-06-22 — — US disclosed
EP-1541145-A1 THE USE OF BENZISOSELENAZOLONE COMPOUNDS AGAINST ISCHEMIC MYOCARDIAL DAMAGE Institute of Materia, Chinese Academy of Medical Sciences (CN) 2005-06-15 — — EP disclosed
EP-0257306-B1 DISELENOBIS BENZOIC ACID AMIDES OF PRIMARY HETEROCYCLIC AMINES, PROCESS FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOUNDS COMPRISING THE SAME A. Nattermann & Cie. GmbH (DE) 1990-09-12 — — EP disclosed
US-4910313-A Containing a heterocyclic ring NATTERMANN & CIE GMBH (DE) 1990-03-20 — — US disclosed
EP-0154851-B1 BENZISOSELENAZOLETHIONES,PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PRODUCTS CONTAINING THESE COMPOUNDS A. Nattermann & Cie. GmbH (DE) 1989-08-02 — — EP disclosed
EP-0100899-B1 BENZISOSELENAZOLONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM A. Nattermann & Cie. GmbH (DE) 1988-06-15 — — EP disclosed
EP-0257306-A1 Diselenobis benzoic acid amides of primary heterocyclic amines, process for producing the same and pharmaceutical compounds comprising the same A. Nattermann & Cie. GmbH (DE) 1988-03-02 — — EP disclosed
US-4711961-A Benzisoselenazolethiones and process for the treatment of various diseases in humans A. NATTERMANN & CIE GMBH (DE) 1987-12-08 — — US disclosed
US-4550168-A Benzisoselenazolones and a process for the treatment of inflammatory diseases A. NATTERMANN & CIE GMBH (DE) 1985-10-29 — — US disclosed
EP-0154851-A1 Benzisoselenazolethiones,process for their preparation and pharmaceutical products containing these compounds A. Nattermann & Cie. GmbH (DE) 1985-09-18 — — EP disclosed
EP-0100899-A2 Benzisoselenazolones, process for their preparation and pharmaceutical compositions containing them A. Nattermann & Cie. GmbH (DE) 1984-02-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135569-A1 Use of benzisoselenazolone compounds against ischemic myocardial damage TNNI3, TNNT2, MYLK2 METAP2 4321/4885KDM4E 2585/4885ALDH1A1 407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback